alpha-glucosidase inhibitor


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.
Related to alpha-glucosidase inhibitor: thiazolidinedione

α-glucosidase inhibitor

an oral agent that aids in the control of diabetes mellitus by delaying the absorption of glucose from the digestive system.

alpha-glucosidase inhibitor

any of a group of oral antihyperglycemic agents that act by competitive inhibition of alpha-glucosidase, delaying intestinal carbohydrate absorption and lessening postprandial increases in glucose levels.

alpha-glucosidase inhibitor

An oral drug that lowers blood sugars by preventing carbohydrate absorption from the gastrointestinal tract.
See also: inhibitor

α-glu·co·si·dase in·hib·i·tor

(glū-kō'si-dās in-hib'i-tŏr)
Oral agent that aids control of diabetes mellitus by delaying absorption of glucose from digestive system.
References in periodicals archive ?
Digestive enzymes and intestinal adsorbents, such as charcoal, should not be taken at the same time as the alpha-glucosidase inhibitors, as they will decrease the efficacy of the alphaglucosidase inhibitors.
While use of the alpha-glucosidase inhibitors alone is not associated with hypoglycemia, if they are used in combination with other antidiabetic medications, hypoglycemia may occur.
Alpha-glucosidase inhibitors can prolong the processes along the entire intestine, lengthen the duration of carbohydrate absorption, and flatten the blood glucose concentrations over time curve (Bischoff, 1993).
Along with revenue prediction for the overall world market for treating diabetes, that work shows individual forecasts to 2023 for seven submarkets: -- Human insulins and analogues -- Alpha-glucosidase inhibitors -- Biguanides -- DPP-4 inhibitors -- Meglitinides -- Sulphonylureas -- Thiazolidinediones (glitazones).
Other oral agents include sulphonylureas, thiazolidinediones (TZDs or glitazones), glinides and alpha-glucosidase inhibitors.
Type 2 Diabetes: Disease Background and Prevalence - Pathophysiology and Risk Factors - Type 2 Diabetes and Cardiovascular Disease - Prevalence of Type 2 Diabetes - Overview of Current Drug Therapies - Sulfonylureas - Meglitinides - Alpha-Glucosidase Inhibitors - Biguanides - Peroxisome Proliferator-Activated Receptor-Gamma Agonists - Glucagon-Like Peptide-1 Analogues - Amylin Analogues - The PROactive Study: Revealing a Potential Breakthrough Treatment for Cardiovascular Disease in Type 2 Diabetes - The Role of PPAR in Cardiovascular Disease - PROactive Study Design - PROactive Study Results - Shortcomings of the PROactive Study - Outlook Companies mentioned: - Eli Lilly - GlaxoSmithKline - Takeda
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20